Evidence map›Paper›PMID 38751322›Full record

ArticleJournal of magnetic resonance imaging : JMRI2025

Investigating MRI-Associated Biological Aspects of Racial Disparities in Prostate Cancer for African American and White Men.

Fatemeh Zabihollahy, Qi Miao, Sohaib Naim, Ida Sonni, Sitaram Vangala, Harrison Kim, William Hsu, Anthony Sisk, Robert Reiter, Steven S Raman and 1 more

Abstract read
In one paragraph

Article in Journal of magnetic resonance imaging : JMRI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Quantitative Prostate MRI, From theAJR. American journal of roentgenology · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Fatemeh ZabihollahyDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID https://orcid.org/0000-0003-3362-1009
Qi MiaoDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID https://orcid.org/0000-0003-2235-8997
Sohaib NaimDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Ida SonniDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Sitaram VangalaDepartment of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Harrison KimDepartment of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
William HsuDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Anthony SiskDepartment of Pathology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Robert ReiterDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Steven S RamanDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Kyunghyun SungDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID https://orcid.org/0000-0003-4175-5322

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6M
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer ClassificationR01CA248506 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SUNG, KYUNG HYUN, WU, HOLDEN H · 2020 to 2024
$3.0M
Racially-associated MRI analysis and modeling for predicting aggressive prostate cancerR01CA272702 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Harrison Kim, Kyung Hyun Sung · 2023 to 2026
$2.4M
Division of Cancer Prevention, National Cancer Institute R01-CA248506Integrated Diagnostics Program of the Departments of Radiological Sciences and Pathology in the UCLA David Geffen School of MedicineNational Cancer Research Institute R01-CA272702NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA092131NCI NIH HHS R01 CA248506NCI NIH HHS R01 CA272702
6 · The paper itself

Abstract

backgroundUnderstanding the characteristics of multiparametric MRI (mpMRI) in patients from different racial/ethnic backgrounds is important for reducing the observed gaps in clinical outcomes. PURPOSE: To investigate the diagnostic performance of mpMRI and quantitative MRI parameters of prostate cancer (PCa) in African American (AA) and matched White (W) men. STUDY TYPE: Retrospective. SUBJECTS: One hundred twenty-nine patients (43 AA, 86 W) with histologically proven PCa who underwent mpMRI before radical prostatectomy. FIELD STRENGTH/SEQUENCE: 3.0 T, T2-weighted turbo spin echo imaging, a single-shot spin-echo EPI sequence diffusion-weighted imaging, and a gradient echo sequence dynamic contrast-enhanced MRI with an ultrafast 3D spoiled gradient-echo sequence. ASSESSMENT: The diagnostic performance of mpMRI in AA and W men was assessed using detection rates (DRs) and positive predictive values (PPVs) in zones defined by the PI-RADS v2.1 prostate sector map. Quantitative MRI parameters, including K STATISTICAL TESTS: Weighted Pearson's chi-square and Mann-Whitney U tests with a statistically significant level of 0.05 were used to examine differences in DR and PPV and to compare parameters between AA and matched W men, respectively.

resultsA total number of 264 PCa lesions were identified in the study cohort. The PPVs in the peripheral zone (PZ) and posterior prostate of mpMRI for csPCa lesions were significantly higher in AA men than in matched W men (87.8% vs. 68.1% in PZ, and 89.3% vs. 69.6% in posterior prostate). The K DATA

conclusionThis study demonstrated race-related differences in the diagnostic performances and quantitative MRI measures of csPCa that were not reflected in age, PSA, and prostate volume. EVIDENCE LEVEL: 3 TECHNICAL EFFICACY: Stage 2.

Indexed as

Black or African AmericanMagnetic Resonance ImagingProstatic NeoplasmsWhiteAgedContrast MediaHumansMaleMiddle AgedMultiparametric Magnetic Resonance ImagingNeoplasm GradingProstateProstatectomyRetrospective StudiesContrast Mediahealth disparitymulti‐parametric MRIprostate cancer

Identifiers

PMID38751322
PMCPMC11564416

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.